On the stock market since 2000, it operates in the world of health and science. It has 2,931 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
A loss of $2.4B against $2.0B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0003. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ENDPQ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ENDPQ has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.